颈动脉内膜切除术后再狭窄的治疗:单中心回顾性研究
该单中心回顾性研究比较了颈动脉内膜切除术后再狭窄的开放手术与血管内治疗技术。共纳入45例再狭窄手术(开放手术11例,血管内治疗34例),血管内治疗组住院时间更短、血肿更少,主要并发症和生存率无显著差异,但未能确定最佳血管内策略。
要点
- 血管内治疗与开放手术治疗颈动脉再狭窄的主要并发症和生存率相当。
- 血管内治疗组血肿更少且住院时间更短。
- 不同血管内技术(单纯球囊、支架、药物涂层球囊)间未显示显著差异。
核心结论
- 血管内治疗与迭代开放手术治疗颈动脉再狭窄在主要并发症、新发再狭窄或生存方面等效,且血肿更少、住院时间更短。
- 未能确定最佳血管内策略,建议开展比较不同血管内策略的对照研究。
研究设计与样本
- 单中心回顾性研究,2010年1月至2017年11月共1218例颈动脉手术,其中45例为颈动脉内膜切除术后再狭窄手术。
- 45例中开放手术11例,血管内治疗34例(单纯经腔血管成形术7例、颈动脉支架9例、药物涂层球囊18例)。
- 围手术期数据包括累积死亡率和并发症率及住院时间,术后结果包括生存、超声发现症状性再狭窄>50%或无症状狭窄>70%及再干预。
- 使用Fisher精确检验分析,长期结果用Kaplan-Meier估计和log rank检验比较,P<0.05为显著。
主要发现
- 血管内治疗组有1例因术后大面积卒中导致二次死亡。
- 开放手术组与血管内治疗组累积死亡率和并发症率无显著差异(2.9%,P=0.756)。
- 开放手术组血肿3例,血管内治疗组1例(P=0.04)。
- 血管内治疗组住院时间更短(P<0.001)。
- 两组2年生存率(86% vs. 100%,log rank=0.804)和无复发性再狭窄生存率(log rank=0.114)无差异。
关键数值与推荐
- 症状性再狭窄>50%或无症状狭窄>70%经超声诊断。
- 累积死亡率和并发症率2.9%,P=0.756(开放手术 vs. 血管内治疗)。
- 2年生存率86% vs. 100%,log rank=0.804;无复发性再狭窄生存率log rank=0.114。
- 不同血管内技术比较:无再干预生存率DCB组94% vs. PTA和CAS组100%(log rank=0.585);无复发性再狭窄生存率DCB组87% vs. PTA和CAS组100%(log rank=0.137);总生存率DCB和CAS组89% vs. PTA组100%(log rank=0.286)。
临床怎么用
- 对于颈动脉内膜切除术后再狭窄,血管内治疗可作为开放手术的等效替代,尤其适合希望缩短住院时间和减少血肿风险的患者。
- 具体血管内技术选择需个体化,因本研究未证明某种技术优于其他。
- 术后需超声随访监测再狭窄,症状性>50%或无症状>70%时考虑再干预。
局限性
- 单中心回顾性研究,样本量小(45例),可能存在选择偏倚。
- 不同血管内技术亚组样本量小,统计效能不足。
- 缺乏长期随访数据和随机对照设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To compare the different techniques for the treatment of carotid restenosis after carotid artery endarterectomy (CAE). METHODS: Among 1,218 carotid surgeries carried out in our center between January 2010 and November 2017, 45 procedures were performed for carotid restenosis after CAE, including 11 by iterative conventional surgery and 34 with endovascular techniques (7 transluminal angioplasties alone [TLA], 9 carotid artery stenting [CAS], and 18 angioplasties with active balloons [drug-coated balloon {DCB}]). Perioperative data (cumulated rate of morbimortality [CRMM], duration of hospitalization) and postoperative results (survival, symptomatic restenoses > 50% or asymptomatic stenoses > 70% on ultrasound, reinterventions) were collected retrospectively and analyzed with Fisher's exact test. The long-term results were estimated according to the Kaplan-Meier estimator and were compared with the log rank test (P < 0.05 was regarded as significant). RESULTS: There was one secondary death due to a massive postoperative stroke in the endovascular (ENDO) group. No significant difference regarding CRMM (2.9%, P = 0.756) between the iterative conventional surgery (open surgery; OS) and the ENDO groups of was observed. Three hematomas were found in the OS group versus one in the ENDO group (P = 0.04). The length of hospital stay was shorter in the ENDO group (P < 0.001). No difference was found between the ENDO group and the OS group regarding the two-year survival or the survival without recurrent restenosis (86 vs. 100%, log rank = 0.804, and log rank = 0.114). There were 5 restenoses >70% and two reinterventions in the ENDO group (P > 0.05). The comparison of the different endovascular techniques did not show significant differences regarding the CRMM, the one-year overall survival, the survival without recurrent restenosis, or the survival without reintervention (89% in the DCB and CAS groups vs. 100% in the percutaneous transluminal angioplasty [PTA] group, log rank = 0.286; 87% in the DCB group vs. 100% in the PTA and CAS groups, log rank = 0.137; and 94% in the DCB group vs. 100% in the PTA and CAS groups, log rank = 0.585, respectively). CONCLUSIONS: In our experience, endovascular procedures are equivalent to iterative conventional surgery for the treatment of carotid restenoses in terms of major complications, news restenoses, or survival with less hematoma and a shorter duration of hospitalization. We however could not identify the best endovascular strategy in this indication, and a controlled study comparing the various endovascular strategies is proposed.
引用
- Haupert G, Ammi M, Hersant J, et al. Treatment of Carotid Restenoses after Endarterectomy: A Retrospective Monocentric Study. Ann Vasc Surg. 2020. PMID: 31923595. doi:10.1016/j.avsg.2019.10.103
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。